Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialisation of products for the treatment of cancer and other severe, immune, inflammatory conditions.
“At Celgene, we seek to deliver truly innovative and life-changing drugs for patients.”
Globally, there are more than 300 clinical trials at major medical centres using compounds from Celgene. Investigational compounds are being studied for patients with incurable haematological and solid tumour cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukaemia (CLL), non-Hodgkin’s lymphoma (NHL), small cell lung cancer and prostate cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so.